TY - JOUR
T1 - Response to Lamivudine Treatment in Children with Chronic Hepatitis B Virus Infection
AU - Hagmann, Stefan
AU - Chung, May
AU - Rochford, Gemma
AU - Jani, Mudra
AU - Trinh-Shevrin, Chau
AU - Sitnitskaya, Yekaterina
AU - Neumann, Avidan U.
AU - Pollack, Henry
PY - 2003/12/1
Y1 - 2003/12/1
N2 - Despite the recent approval of lamivudine for the treatment of children with chronic hepatitis B virus (HBV) infection, there is insufficient information on the kinetics of HBV clearance and the factors that predict a favorable treatment response to lamivudine in this population. In a small retrospective study of 16 HBV-infected children treated with lamivudine, we examined changes in virus load and other factors associated with hepatitis B e antigen (HBeAg) clearance. High pretherapy alanine aminotransferase level, low serum HBV DNA load, and age at the start of treatment were independently associated with HBeAg clearance. HBeAg clearance was also associated with the achievement of specific levels of virus suppression, and failure to achieve those levels was associated with the development of lamivudine resistance. Additional studies are necessary to provide better indications and guidelines for the treatment of children with chronic HBV infection.
AB - Despite the recent approval of lamivudine for the treatment of children with chronic hepatitis B virus (HBV) infection, there is insufficient information on the kinetics of HBV clearance and the factors that predict a favorable treatment response to lamivudine in this population. In a small retrospective study of 16 HBV-infected children treated with lamivudine, we examined changes in virus load and other factors associated with hepatitis B e antigen (HBeAg) clearance. High pretherapy alanine aminotransferase level, low serum HBV DNA load, and age at the start of treatment were independently associated with HBeAg clearance. HBeAg clearance was also associated with the achievement of specific levels of virus suppression, and failure to achieve those levels was associated with the development of lamivudine resistance. Additional studies are necessary to provide better indications and guidelines for the treatment of children with chronic HBV infection.
UR - http://www.scopus.com/inward/record.url?scp=0344688313&partnerID=8YFLogxK
U2 - 10.1086/378739
DO - 10.1086/378739
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 14614664
AN - SCOPUS:0344688313
SN - 1058-4838
VL - 37
SP - 1434
EP - 1440
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 11
ER -
